Allied Biotech Corp(TW:1780)
NT$23.700.00 (0.00%)
TW:1780
Allied Biotech Corp financials statements
NT$23.70
At close:0.00 (0.00%)
Allied Biotech Corp (1780) Ratios
Allied Biotech Corp Ratios
TW:1780's free cash flow for Q2 2026 was NT$96.94M. For the 2026 fiscal year, TW:1780's free cash flow was decreased by NT$-19.91M and operating cash flow was NT$51.57M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.90 | 1.67 | 1.76 | 1.72 | 1.33 |
| Quick Ratio | 1.26 | 1.14 | 1.03 | 1.05 | 0.95 |
| Cash Ratio | 0.99 | 0.98 | 0.75 | 0.76 | 0.56 |
| Solvency Ratio | 0.22 | 0.15 | 0.18 | 0.22 | 0.06 |
| Operating Cash Flow Ratio | 0.27 | 0.22 | 0.17 | 0.18 | 0.05 |
| Short-Term Operating Cash Flow Coverage | 0.31 | 0.25 | 0.19 | 0.22 | 0.06 |
| Net Current Asset Value | NT$ 664.28M | NT$ 601.77M | NT$ 546.76M | NT$ 535.53M | NT$ 425.65M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.35 | 0.42 | 0.38 | 0.38 | 0.51 |
| Debt-to-Equity Ratio | 0.59 | 0.80 | 0.68 | 0.71 | 1.15 |
| Debt-to-Capital Ratio | 0.37 | 0.44 | 0.41 | 0.41 | 0.54 |
| Long-Term Debt-to-Capital Ratio | 0.03 | 0.04 | 0.06 | 0.07 | 0.00 |
| Financial Leverage Ratio | 1.69 | 1.89 | 1.78 | 1.84 | 2.26 |
| Debt Service Coverage Ratio | 0.29 | 0.20 | 0.25 | 0.31 | 0.07 |
| Interest Coverage Ratio | 6.95 | 6.31 | 6.85 | 8.66 | 2.56 |
| Debt to Market Cap | 0.32 | 0.56 | 0.51 | 0.62 | 0.85 |
| Interest Debt Per Share | 7.76 | 10.06 | 8.46 | 8.91 | 13.20 |
| Net Debt to EBITDA | -0.23 | -0.11 | 0.87 | 0.59 | 5.21 |
| Profitability Margins | |||||
| Gross Profit Margin | 36.33% | 32.02% | 34.21% | 37.82% | 38.13% |
| EBIT Margin | 21.36% | 17.84% | 18.79% | 27.46% | 16.50% |
| EBITDA Margin | 28.54% | 25.52% | 28.43% | 37.75% | 13.90% |
| Operating Profit Margin | 14.17% | 10.92% | 12.31% | 14.20% | 4.26% |
| Pretax Profit Margin | 19.32% | 16.12% | 16.99% | 25.82% | 2.60% |
| Net Profit Margin | 15.24% | 12.51% | 13.52% | 20.47% | 1.93% |
| Continuous Operations Profit Margin | 15.24% | 12.51% | 13.52% | 20.47% | 1.93% |
| Net Income Per EBT | 78.88% | 77.62% | 79.60% | 79.30% | 74.19% |
| EBT Per EBIT | 136.32% | 147.57% | 137.95% | 181.80% | 60.99% |
| Return on Assets (ROA) | 6.19% | 4.47% | 4.69% | 6.72% | 0.53% |
| Return on Equity (ROE) | 10.49% | 8.44% | 8.33% | 12.40% | 1.21% |
| Return on Capital Employed (ROCE) | 9.32% | 6.99% | 7.10% | 7.90% | 2.63% |
| Return on Invested Capital (ROIC) | 4.78% | 3.17% | 3.58% | 3.97% | 0.92% |
| Return on Tangible Assets | 6.19% | 4.49% | 4.92% | 7.09% | 0.63% |
| Earnings Yield | 5.79% | 6.04% | 6.26% | 10.95% | 0.90% |
| Efficiency Ratios | |||||
| Receivables Turnover | 6.09 | 6.07 | 6.56 | 5.99 | 6.42 |
| Payables Turnover | 20.16 | 23.92 | 19.48 | 12.73 | 11.82 |
| Inventory Turnover | 1.06 | 1.04 | 0.79 | 0.75 | 0.82 |
| Fixed Asset Turnover | 1.57 | 1.42 | 1.21 | 1.15 | 1.08 |
| Asset Turnover | 0.41 | 0.36 | 0.35 | 0.33 | 0.28 |
| Working Capital Turnover Ratio | 1.22 | 1.25 | 1.14 | 1.33 | 1.29 |
| Cash Conversion Cycle | 386.92 | 395.92 | 500.09 | 520.72 | 468.89 |
| Days of Sales Outstanding | 59.93 | 60.16 | 55.66 | 60.93 | 56.87 |
| Days of Inventory Outstanding | 345.10 | 351.03 | 463.17 | 488.47 | 442.91 |
| Days of Payables Outstanding | 18.10 | 15.26 | 18.74 | 28.68 | 30.89 |
| Operating Cycle | 405.03 | 411.18 | 518.82 | 549.40 | 499.78 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 2.24 | 2.32 | 1.44 | 1.72 | 0.76 |
| Free Cash Flow Per Share | 1.90 | 2.04 | 0.94 | 1.15 | 0.24 |
| Dividend Paid and CapEx Coverage Ratio | 1.68 | 2.07 | 0.85 | 1.61 | 0.57 |
| Capital Expenditure Coverage Ratio | 6.47 | 8.35 | 2.87 | 3.01 | 1.45 |
| Operating Cash Flow Coverage Ratio | 0.30 | 0.23 | 0.17 | 0.20 | 0.06 |
| Operating Cash Flow to Sales Ratio | 0.26 | 0.28 | 0.19 | 0.23 | 0.11 |
| Free Cash Flow Yield | 8.21% | 11.79% | 5.77% | 8.18% | 1.54% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 17.24 | 16.52 | 15.93 | 9.12 | 108.93 |
| Price-to-Sales (P/S) Ratio | 2.63 | 2.07 | 2.16 | 1.87 | 2.15 |
| Price-to-Book (P/B) Ratio | 1.81 | 1.40 | 1.33 | 1.13 | 1.34 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 12.18 | 8.48 | 17.34 | 12.23 | 64.79 |
| Price-to-Operating Cash Flow Ratio | 10.30 | 7.47 | 11.30 | 8.16 | 20.07 |
| Price-to-Earnings Growth (PEG) Ratio | 0.62 | 5.62 | -0.47 | 0.01 | -1.31 |
| Enterprise Value Multiple | 8.99 | 8.00 | 8.47 | 5.54 | 20.67 |
| Enterprise Value | 2.18B | 1.65B | 1.73B | 1.50B | 1.94B |
| EV to EBITDA | 8.99 | 8.00 | 8.47 | 5.54 | 20.67 |
| EV to Sales | 2.57 | 2.04 | 2.41 | 2.09 | 2.87 |
| EV to Free Cash Flow | 11.88 | 8.37 | 19.33 | 13.67 | 86.63 |
| EV to Operating Cash Flow | 10.04 | 7.37 | 12.60 | 9.12 | 26.84 |
| Tangible Book Value Per Share | 12.75 | 12.32 | 11.17 | 11.22 | 10.24 |
| Shareholders’ Equity Per Share | 12.75 | 12.41 | 12.21 | 12.41 | 11.34 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.21 | 0.22 | 0.20 | 0.21 | 0.26 |
| Revenue Per Share | 8.78 | 8.38 | 7.53 | 7.51 | 7.10 |
| Net Income Per Share | 1.34 | 1.05 | 1.02 | 1.54 | 0.14 |
| Tax Burden | 0.79 | 0.78 | 0.80 | 0.79 | 0.74 |
| Interest Burden | 0.90 | 0.90 | 0.90 | 0.94 | 0.16 |
| Research & Development to Revenue | 0.03 | 0.03 | 0.04 | 0.03 | 0.04 |
| SG&A to Revenue | 0.19 | 0.18 | 0.18 | 0.20 | 0.18 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.32 | 1.72 | 1.41 | 0.89 | 4.12 |
Currency in TWD
